Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study. Issue 2 (February 2017)

• Record Type: Journal Article
• Authors: Ristow, O.; Otto, S.; Geiß, C.; Kehl, V.; Berger, M.; Troeltzsch, M.; Koerdt, S.; Hohlweg-Majert, B.; Freudlsperger, C.; Pautke, C.
• Is Part Of: International journal of oral & maxillofacial surgery. Volume 46:Issue 2(2017:Feb.)
• Page Start: 157
• Page End: 166
• Publication Date: 2017-02
• Subjects: necrosis of the jaw -- BRONJ -- DRONJ -- MRONJ -- ONJ -- bisphosphonate -- osteonecrosis -- bone fluorescence -- tetracycline -- auto-fluorescence -- therapy -- bone -- VELscope; Mouth -- Surgery -- Periodicals; Maxilla -- Surgery -- Periodicals; Dentistry -- Periodicals; Dentistry, Operative; Oral Surgical Procedures; Surgery, Oral; Dentistry; Maxilla -- Surgery; Mouth -- Surgery; Electronic journals; Periodicals; 617.52059
• DOI: 10.1016/j.ijom.2016.10.008
• Languages: English
• ISSNs: 0901-5027

Abstract

Abstract: Recent studies have indicated that bone shows auto-fluorescence under an appropriate fluorescence lamp. The aim of this preliminary study was to compare the success rates of the established tetracycline fluorescence-guided bone surgery with auto-fluorescence-guided bone surgery in the treatment of medication-related osteonecrosis of the jaw (MRONJ). Forty patients suffering from MRONJ were referred for surgical treatment and were divided randomly into two groups: auto-fluorescence ( n = 20) or tetracycline fluorescence ( n = 20) guided bone surgery. The primary endpoint was treatment success, defined as the absence of exposed bone at 8 weeks after surgery. Secondary outcomes assessed were mucosal integrity, signs of infection, pain, and loss of sensitivity; these were evaluated descriptively at 10 days, 8 weeks, 6 months, and 1 year after surgery. At 8 weeks postoperative, 18/20 patients (90%) in the auto-fluorescence group and 17/20 patients (85%) in the tetracycline fluorescence group showed mucosal integrity ( P > 0.05). At the last follow-up, 94% in the auto-fluorescence group and 89% in the tetracycline fluorescence group presented complete mucosal coverage with no exposed bone, infection, or pain ( P > 0.05). There was no significant difference between the two techniques for any of the secondary outcomes ( P > 0.05). The results of this preliminary study show that auto-fluorescence-guided bone surgery has comparable success rates to the established tetracycline fluorescence-guided bone surgery.